Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.
Intermittent self-catheterisation in MS.
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation.
Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.
Antigen-specific tolerance by autologous myelin Peptide-coupled cells: a phase 1 trial in multiple sclerosis.
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
Inflammatory cortical demyelination in early multiple sclerosis.
Cognitive impairment in multiple sclerosis.
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome.
Merck: Regulatory Update on Cladribine Tablets
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Pharmacology and therapeutic potential of interferons.
Interferon Beta-1b may reverse axonal dysfunction in multiple sclerosis.
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate.
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants.
Inflammation-induced fatigue: Exploring neurobiological mechanisms and potential treatments
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
Multiple sclerosis: risk factors, prodromes, and potential causal pathways.

Pages